FDA to Restrict Non-Approved GLP-1 Drugs from Compounding Pharmacies

The Food and Drug Administration (FDA) announced plans on February 6, 2026, to restrict the use of GLP-1 active pharmaceutical ingredients in drugs that have not been approved by the agency. This includes compounded medications offered by companies like Hims & Hers, as well as other compounding pharmacies.

Safeguarding Drug Quality and Consumer Safety

According to a press release, the FDA’s actions are intended to protect consumers from medications where the quality, safety, and effectiveness cannot be verified. FDA Commissioner Martin A. Makary, MD, MPH, stated that these measures are crucial for public health.

Did You Know? The FDA is also planning to address direct-to-consumer advertising related to these non-approved compounded products.

Restrictions on Advertising Claims

The FDA intends to take action against companies making specific claims about non-FDA-approved compounded drugs. Commissioner Makary wrote that companies “cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA.”

these companies are prohibited from stating that compounded drugs contain the same active ingredient as FDA-approved drugs or that they have been clinically proven to deliver results for patients.

Expert Insight: The FDA’s move underscores the importance of regulatory oversight in pharmaceutical compounding, particularly as demand for certain medications rises and alternative sources emerge. This action aims to ensure patients receive medications that meet established standards for quality and efficacy.

What Could Happen Next

The FDA’s announcement could lead to increased scrutiny of compounding pharmacies and a reduction in the availability of non-FDA-approved GLP-1 medications. Enforcement actions, including warning letters and potential legal challenges, will follow. Consumers may need to rely more heavily on FDA-approved medications, potentially impacting access and cost.

Frequently Asked Questions

What are GLP-1s?

The article states the FDA is restricting GLP-1 active pharmaceutical ingredients, but does not define what GLP-1s are.

Which companies are affected by this announcement?

The FDA specifically mentioned Hims & Hers and other compounding pharmacies as being affected by the planned restrictions.

What is the FDA’s concern with compounded drugs?

The FDA cannot verify the quality, safety, or efficacy of non-FDA-approved compounded drugs, leading to the planned restrictions.

How might these changes impact access to medications for individuals currently using compounded GLP-1s?